UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Sells 910,050 Shares of Insulet Corporation $PODD

Key Points

• UBS Asset Management significantly reduced its holdings in Insulet Corporation by selling 910,050 shares, bringing their total ownership down to about 714,953 shares in the first quarter.
• Insulet's stock was recently rated as a "Moderate Buy" by analysts, with a consensus target price of $335.12, reflecting positive sentiment about its future performance.
• The company reported a 32.9% year-over-year revenue increase for the last quarter, with earnings of $1.17 per share, surpassing analyst estimates and solidifying its growth trajectory.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC decreased its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 56.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 714,953 shares of the medical instruments supplier's stock after selling 910,050 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 1.02% of Insulet worth $187,754,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Nissay Asset Management Corp Japan ADV raised its stake in shares of Insulet by 0.6% in the first quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier's stock valued at $2,222,000 after acquiring an additional 48 shares during the last quarter. Brooklyn Investment Group boosted its stake in Insulet by 7.0% in the first quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier's stock valued at $209,000 after acquiring an additional 52 shares during the last quarter. OLD National Bancorp IN boosted its stake in Insulet by 6.7% in the first quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock valued at $231,000 after acquiring an additional 55 shares during the last quarter. Cooper Financial Group boosted its stake in Insulet by 5.7% in the first quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock valued at $283,000 after acquiring an additional 58 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in shares of Insulet by 23.1% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock valued at $82,000 after buying an additional 59 shares during the period.

Insider Transactions at Insulet

In related news, SVP Prem Singh sold 687 shares of the company's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

PODD has been the subject of a number of recent analyst reports. The Goldman Sachs Group assumed coverage on shares of Insulet in a research report on Friday, May 30th. They issued a "buy" rating and a $380.00 price objective for the company. Oppenheimer raised their price objective on Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a report on Monday. Barclays raised their price objective on Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a report on Thursday, August 21st. Sanford C. Bernstein restated an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Finally, Wells Fargo & Company boosted their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. Sixteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $335.12.

Insulet Stock Up 0.1%

Shares of PODD opened at $337.94 on Friday. Insulet Corporation has a 52 week low of $225.28 and a 52 week high of $353.50. The firm has a market cap of $23.79 billion, a P/E ratio of 102.72, a price-to-earnings-growth ratio of 2.80 and a beta of 1.36. The firm's 50-day simple moving average is $310.77 and its 200 day simple moving average is $291.47. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. During the same quarter in the prior year, the business earned $0.55 EPS. Insulet's quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.